Latest: Executive Chair Bought $250K of Shares · Apr 2026
2 filings analyzed·Latest 2026-04-27
Insider buys
2
Insider sells
0
Unique insiders
2
Direction
Net buying
April 2026
2026-04-27
high
LoPriore Vincent S
Buy
Executive Chairman
6,250,000 shares
$250,000
@ $0.04
Significance8/10
Insider accumulates 6.25M shares at depressed valuation while stock trades near 52-week lows amid unprofitable operations.
An insider has made substantial open-market purchases of over six million shares in Hepion Pharmaceuticals, adding to existing holdings at a time when the stock is trading dramatically below its recent highs and has lost significant value over recent months. The company is burning cash with no revenue and ongoing quarterly losses, indicating it remains in a development or distressed phase. This is a classic knife-catching scenario where an insider is betting on either a strategic inflection, clinical trial milestone, or acquisition despite severe financial headwinds. The conviction signal is meaningful—the insider is putting real capital to work and increasing exposure by a quarter of their holdings—but the fundamental weakness and extreme stock underperformance raise questions about whether this is contrarian conviction or capitulation into insolvency risk.
Insider purchases 1.25M shares of HEPA at distressed valuation amid severe stock decline and ongoing losses
An insider has purchased over a million shares of Hepion Pharmaceuticals at a depressed price, signaling belief in a potential turnaround despite the company's dire financial condition. The stock has collapsed significantly from its recent highs and is trading near multi-year lows, suggesting either capitulation selling or a contrarian accumulation opportunity. Fundamentally, Hepion is unprofitable with zero revenue and substantial quarterly losses, indicating the company is in a pre-commercial or failed development stage burning through cash. This insider buy at rock-bottom levels could represent either conviction in hidden value or an attempt to prop up a struggling asset—the distinction matters significantly for investors. Without visibility into the insider's historical track record or upcoming catalysts (clinical trials, partnerships, etc.), this trade warrants close monitoring to determine whether this represents savvy bottom-fishing or a warning sign of desperation.
Add HEPA to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.